ObjectiveTo observe the efficacy and safety of anlotinib capsule combined with vinorelbine soft capsule in the treatment of advanced non-small cell lung cancer(NSCLC).

MethodsThe patients with stage ⅢB/Ⅳ NSCLC confirmed by pathology were treated with anlotinib capsule(12 mg) once a day for 14 days, and combined with vinorelbine soft capsule(60 mg/m²) orally on day 1 and day 8, 21 days for a cycle, and until disease progression or toxicity became intolerant.The objective response rates, disease control rates, progression-free survival, overall survival and adverse reactions were recorded.

ResultsA total of 30 patients were included in this study, which included no complete response cases, 4 partial response cases, 21 stable disease cases and 5 progressive disease cases.The objective remission rate was 13.3%, and the disease control rate was 83.3%.The median progression-free survival was 6.5(6.3-6.9) months, and the median overall survival was 9.9(7.7-11.7) months.In the univariate analysis affecting progression and death, the median progression-free survival time and median survival time in patients with≥60 years old, PS score for 0-1, no smoking history and pathological type of adenocarcinoma were higher than those in patients with age < 60 years old, PS score for 2, smoking history and pathological type of squamous cell carcinoma(P < 0.05 to P < 0.01).The nausea and vomiting(36.7%), fatigue(33.3%) and diarrhea(30%) were the most common adverse reactions, but most of them were grade 1 or 2, which could be improved after symptomatic treatment.

ConclusionsThe anlotinib capsule combined with vinorelbine soft capsule in the treatment of NSCLC can better control the disease progression, achieve the purpose of prolonging the patient′s survival time, and the adverse reactions can be controlled.